Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg
twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a
standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of
elective percutaneous coronary intervention (PCI).